Generic HOMATROPINE METHYLBROMIDE INN entry, pharmaceutical patent expiration information and freedom to operate

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novel Labs Inc	HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE	homatropine methylbromide; hydrocodone bitartrate	SYRUP;ORAL	203535-001	Feb 13, 2017	AA	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Genus Lifesciences	HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE	homatropine methylbromide; hydrocodone bitartrate	SYRUP;ORAL	040613-001	Feb 8, 2008		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Genus	HYCODAN	homatropine methylbromide; hydrocodone bitartrate	TABLET;ORAL	005213-001	Jul 26, 1988	AA	RX	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: September 8, 2026

Homatropine methylbromide is a legacy ophthalmic anticholinergic used to produce mydriasis and cycloplegia and to reduce pain from ocular inflammation. Its commercial profile is small and mature. The principal branded product, Isopto Homatropine, has limited current-market visibility, while generic, institutional, and compounded supply channels appear more important than branded sales. Public sources do not disclose reliable product-level revenue, market share, or forecast data for homatropine methylbromide.

What is homatropine methylbromide used for?

Homatropine methylbromide is an ophthalmic antimuscarinic. It relaxes the iris sphincter and ciliary muscle, producing pupil dilation and loss of accommodation.

The historical U.S. ophthalmic uses include:

Cycloplegic refraction
Diagnostic pupil dilation
Treatment of iridocyclitis and anterior uveitis
Reduction of ciliary spasm and ocular pain associated with inflammation

The product is administered topically as an ophthalmic solution. Historical commercial strengths have included 2% and 5%, although product availability varies by market and supplier.

Homatropine methylbromide is different from homatropine hydrobromide. The two salts should not be treated as interchangeable for regulatory, manufacturing, labeling, or market-sizing purposes.

What is the FDA regulatory status of homatropine methylbromide?

Homatropine methylbromide is an established ophthalmic active ingredient with a long commercial history. Its U.S. market status is constrained by the limited visibility of currently marketed products and the absence of a large contemporary branded franchise.

Historical U.S. labeling for Isopto Homatropine identifies homatropine methylbromide ophthalmic solution as a prescription product used for uveitis and cycloplegia. The label warns against use in patients with untreated narrow-angle glaucoma and identifies anticholinergic adverse effects, including blurred vision, photophobia, increased intraocular pressure, and systemic toxicity in susceptible patients.[1]

The key regulatory distinction is between:

An approved, commercially marketed product;
A product with an approved application but no current commercial distribution;
A compounded preparation;
A product marketed under an abbreviated or legacy regulatory pathway.

Those categories affect substitution, reimbursement, quality controls, and litigation exposure. A historical label alone does not establish current commercial availability.

FDA status and market implications

Regulatory issue	Market implication
Prescription ophthalmic product	Dispensing is controlled through licensed channels
Legacy active ingredient	Limited opportunity for composition-of-matter exclusivity
Small ophthalmic indication set	Low commercial scale relative to glaucoma, antibiotic, and anti-inflammatory products
Product discontinuation or limited distribution	Greater reliance on wholesalers, hospital pharmacies, or compounding pharmacies
Narrow-angle glaucoma warning	Limits use in certain patients and affects prescribing protocols
No biologic component	Biosimilar regulation is not relevant

FDA-listed product information and current labeling should be checked separately from commercial availability. DailyMed, which publishes labeling submitted by manufacturers, is useful for identifying label history but does not establish that a product remains actively supplied.[2]

What patents protect homatropine methylbromide?

The underlying active ingredient is a mature small molecule. Any original composition-of-matter protection would have expired decades ago. The principal commercial risk therefore does not arise from basic molecule patents.

Potentially relevant rights could include:

Formulation patents
Container-closure or preservative systems
Manufacturing processes
Sterile ophthalmic filling methods
Use patents for a specific ocular condition
Device or delivery-system claims

No current high-value patent barrier is apparent from the public profile of the legacy product. The commercial significance of any residual patent would depend on whether it covers the active U.S. product, remains enforceable, and is listed in the FDA Orange Book.

What is the Orange Book status?

The Orange Book identifies approved drug products and, where applicable, patents and regulatory exclusivities submitted by applicants.[3] Homatropine methylbromide does not have the patent profile associated with recently approved ophthalmic products such as combination therapies, sustained-release inserts, or novel delivery systems.

A legacy product may have no listed patent, may have an approved application with limited commercial activity, or may be outside the practical scope of current generic competition because the market is too small to attract multiple ANDA filers. Those are distinct outcomes.

The relevant conclusion is that homatropine methylbromide has low apparent patent protection but also limited evidence of a large, active generic market.

When does homatropine methylbromide lose exclusivity?

Homatropine methylbromide lost any original molecule-level exclusivity long ago. There is no credible basis for identifying a future primary-patent cliff comparable to those affecting recently launched branded medicines.

Exclusivity category	Expected status
Composition of matter	Expired
Original formulation exclusivity	Expired or commercially immaterial
New chemical entity exclusivity	Not applicable to the legacy molecule
Orphan-drug exclusivity	Not identified for the established ophthalmic product
Pediatric exclusivity	No material current protection identified
Patent-term extension	Not relevant to the legacy product profile
Biosimilar exclusivity	Not applicable

The commercial question is therefore availability rather than patent expiry. A supplier can face little patent risk while still encountering sterile manufacturing, quality, scale, and distribution barriers.

Are there Paragraph IV challenges involving homatropine methylbromide?

No major, publicly prominent Paragraph IV litigation campaign is associated with homatropine methylbromide in the way seen for high-revenue ophthalmic products.

A Paragraph IV certification is relevant only when an ANDA applicant challenges an Orange Book-listed patent. If there are no commercially important listed patents, Paragraph IV activity is unlikely to drive market timing.

Potential generic entry scenarios are more likely to involve:

An ANDA relying on an eligible reference product
A 505(b)(2) application using published literature or a listed product
A reformulated ophthalmic solution
A pharmacy-compounded product
Non-U.S. supply that does not qualify as an FDA-approved substitute

The absence of prominent litigation should not be interpreted as evidence of strong patent protection. It is more consistent with a low-value, mature market in which expected returns may not justify litigation or a new filing program.

What formulations are protected by homatropine methylbromide patents?

The commercially relevant formulation is a sterile ophthalmic solution. The formulation challenge is technical rather than primarily patent-driven.

Key development variables include:

Active concentration, historically including 2% and 5%
pH and osmolality
Preservative selection
Chemical stability
Container compatibility
Sterility throughout shelf life
Drop size and dosing consistency
Protection from light and contamination

A reformulated product could obtain protection for a specific formulation or delivery system if it met statutory patentability standards. Such protection would not automatically block conventional homatropine methylbromide solutions.

Sterile ophthalmic manufacturing creates a practical barrier. A manufacturer must validate aseptic processing or terminal sterilization, demonstrate container-closure integrity, control particulates, and meet ophthalmic quality requirements. These costs can exceed the value of a small legacy market.

How large is the homatropine methylbromide market?

Public sources do not provide a dependable standalone global market size for homatropine methylbromide. Commercial datasets frequently combine it with ophthalmic mydriatics, cycloplegics, atropine products, or uveitis therapies.

The addressable market is structurally limited because:

Use is concentrated in ophthalmology.
Treatment is usually episodic or short-term.
Diagnostic dilation has numerous substitutes.
Uveitis treatment typically includes corticosteroids and other anti-inflammatory therapy.
The drug does not treat the underlying cause of most ocular inflammation.
Several competing anticholinergic agents are familiar to eye-care providers.

Relevant alternatives include atropine, cyclopentolate, and, for diagnostic dilation, phenylephrine-containing regimens. These products differ in duration, clinical setting, age group, and side-effect profile.

Competitive comparison

Product or class	Primary role	Relative commercial position
Homatropine methylbromide	Cycloplegia and relief of ciliary spasm; uveitis support	Mature, niche, limited public revenue visibility
Atropine ophthalmic	Strong, long-duration cycloplegia and selected pediatric uses	Broader clinical recognition
Cyclopentolate	Diagnostic cycloplegia and dilation	Common substitute for examination settings
Phenylephrine	Mydriasis without meaningful cycloplegia	Common dilation component
Topical corticosteroids	Inflammation control	Therapeutic substitute or co-therapy in uveitis
Newer sustained-release systems	Extended delivery	Higher innovation and patent potential

Homatropine methylbromide competes on familiarity, clinical utility, and availability rather than on differentiated intellectual property.

What is the financial trajectory of homatropine methylbromide?

The financial trajectory is best characterized as mature, low-growth, and supply-sensitive. No reliable public filings isolate revenue for homatropine methylbromide, and the product is not associated with a publicly traded, high-growth franchise.

Revenue profile

The product’s likely revenue characteristics are:

Low absolute sales compared with major ophthalmic drugs
Limited pricing power
High sensitivity to product discontinuation
Fragmented purchasing across retail, hospitals, clinics, and compounding pharmacies
Limited promotional spending
Potentially volatile revenue when one supplier exits

For a branded supplier, the product may have strategic value as part of a broader ophthalmic portfolio rather than as a standalone growth asset. For a generic or specialty supplier, value may come from dependable supply, limited competition, and institutional contracts.

Margin considerations

Gross margin can be pressured by:

Small batch sizes
Sterile filling costs
Short production runs
Quality-control testing
Inventory expiration
Low annual unit volume
Regulatory maintenance costs
Distributor minimums

The product may have an attractive price per bottle during shortages without generating large total revenue. Shortage pricing should not be mistaken for sustainable market expansion.

Financial outlook

Period	Expected market condition
Historical period	Branded and legacy ophthalmic use
Current mature phase	Low growth, limited public sales data, supply-driven purchasing
Near term	Stable niche demand if at least one reliable supplier remains
Downside case	Discontinuation, shortage, substitution with atropine or cyclopentolate
Upside case	New supplier, hospital contracting, or reformulated product with improved availability

There is no clear catalyst for rapid revenue growth. A meaningful increase would likely require a new approved formulation, a supply disruption affecting substitutes, or expansion into a defined ophthalmic indication.

What manufacturing and intellectual-property barriers affect entry?

Manufacturing is more important than patent protection. An entrant must establish a compliant sterile ophthalmic process and achieve consistent quality at a market scale that may be modest.

The main barriers are:

Development of a stable sterile solution.
Validation of the filling and packaging process.
Demonstration of product quality and microbial control.
Reliable sourcing of pharmaceutical-grade active ingredient.
Efficient regulatory maintenance for a small product.
Distribution economics across a fragmented customer base.

Active pharmaceutical ingredient sourcing can also create concentration risk. If the market depends on a small number of qualified suppliers, a manufacturing interruption can cause shortages even when no patent blocks entry.

What patent litigation and settlement agreements affect the market?

No major publicly visible patent litigation or settlement agreement currently defines the homatropine methylbromide market. The absence of settlements is consistent with a legacy product that lacks a high-value patent cliff and does not support the economics of extensive branded-generic litigation.

Litigation risk could increase if a company introduced:

A novel sustained-release ocular insert
A proprietary preservative-free formulation
A combination product
A new method of treating a defined inflammatory condition
A device with claims covering dose delivery or retention

Those rights would protect the new product, not necessarily conventional homatropine methylbromide solution.

What generic entry risks exist?

The principal entry risk to an incumbent is commercial substitution rather than a court-ordered generic launch.

High-risk scenarios

A low-cost manufacturer receives approval and secures national distribution.
A hospital or buying group switches to a substitute anticholinergic.
Compounding pharmacies expand supply during a shortage.
A branded supplier discontinues the product, eliminating brand loyalty.
Cyclopentolate or atropine captures diagnostic or cycloplegic demand.

Low-risk scenarios

The market remains too small for multiple entrants.
Sterile manufacturing costs deter new suppliers.
Prescribers retain a preference for a known formulation.
Supply remains concentrated but reliable.
No new product obtains a clinically meaningful delivery advantage.

The risk profile is asymmetric: a new entrant may not need to overcome strong patents, but it must achieve sufficient volume to cover regulatory and manufacturing costs.

How does homatropine methylbromide compare with competing ophthalmic drugs?

Homatropine methylbromide has a shorter-duration and narrower commercial role than atropine in many treatment settings, while cyclopentolate is often better positioned for routine diagnostic cycloplegia. Phenylephrine competes for dilation but does not provide equivalent cycloplegia.

Its strongest remaining commercial position is in selected ophthalmic inflammatory protocols where clinicians value anticholinergic relief of ciliary spasm and prevention of posterior synechiae. Its weakest position is routine diagnostic use where alternatives are widely available and the clinical workflow favors short-duration products.

Key Takeaways

Homatropine methylbromide is a mature ophthalmic anticholinergic with limited public revenue visibility.
The original molecule-level patent estate has expired.
No major current Paragraph IV campaign, patent litigation, or settlement appears to define the market.
Regulatory and commercial availability matter more than patent expiry.
Sterile ophthalmic manufacturing is the main practical entry barrier.
Revenue is likely niche, low-growth, and sensitive to supplier discontinuation or shortage.
Atropine, cyclopentolate, and phenylephrine constrain pricing power and market expansion.
A new formulation or delivery system could create protectable value, but conventional solution products have limited differentiation.
Product-level financial forecasts should be treated cautiously because public filings do not isolate homatropine methylbromide sales.

FAQs

Is homatropine methylbromide still commercially available in the United States?

Availability is limited and may vary by supplier, strength, and distribution channel. Historical branded availability does not establish continuous current supply.

Is homatropine methylbromide the same as atropine?

No. Both are anticholinergic ophthalmic agents, but they differ in chemical structure, duration, labeling, dosing, and clinical use.

Does homatropine methylbromide have biosimilar competition?

No. Biosimilar regulation applies to biologic products. Homatropine methylbromide is a small-molecule drug.

Can a compounded homatropine methylbromide product replace an FDA-approved product?

A compounded preparation may be used in appropriate circumstances under applicable federal and state requirements, but it is not automatically therapeutically or regulatorily equivalent to an FDA-approved product.

Is homatropine methylbromide an attractive licensing opportunity?

The molecule alone is unlikely to support a large licensing transaction. The stronger opportunity would involve a differentiated formulation, preservative-free delivery system, sustained-release technology, or a defined clinical indication with commercial demand.

References

Alcon Laboratories, Inc. (n.d.). Isopto Homatropine: Homatropine hydrobromide ophthalmic solution prescribing information. U.S. Food and Drug Administration labeling archive.
National Library of Medicine. (n.d.). DailyMed: Homatropine methylbromide and ophthalmic product labeling. https://dailymed.nlm.nih.gov/
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

US Patents:	0
Tradenames:	8
Applicants:	15
NDAs:	18
Drug Master File Entries:	4
Raw Ingredient (Bulk) Api Vendors:	48
DailyMed Link:	HOMATROPINE METHYLBROMIDE at DailyMed

HOMATROPINE METHYLBROMIDE - Generic Drug Details

What are the generic drug sources for homatropine methylbromide and what is the scope of patent protection?

Summary for HOMATROPINE METHYLBROMIDE

Anatomical Therapeutic Chemical (ATC) Classes for HOMATROPINE METHYLBROMIDE

US Patents and Regulatory Information for HOMATROPINE METHYLBROMIDE

Homatropine Methylbromide Market Dynamics, FDA Status, Patent Exposure, and Financial Outlook